These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28232379)

  • 1. A longer look at trial evidence of bioresorbable vascular scaffolds.
    Brugaletta S; Sabate M
    Heart; 2017 Jul; 103(14):1061-1062. PubMed ID: 28232379
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary bifurcations: still the touchstone of drug-eluting stents and bioresorbable vascular scaffolds?
    von Birgelen C; van Houwelingen KG; Lam MK
    Rev Esp Cardiol (Engl Ed); 2014 Oct; 67(10):787-9. PubMed ID: 25262123
    [No Abstract]   [Full Text] [Related]  

  • 4. Coronary artery aneurysms formation within Everolimus-eluting stents and bioresorbable vascular scaffolds.
    Lee WC; Chung WJ; Fang HY; Wu CJ
    Int J Cardiol; 2016 Mar; 206():58-60. PubMed ID: 26774833
    [No Abstract]   [Full Text] [Related]  

  • 5. Coronary bioresorbable vascular scaffolds: requiescant in pace?
    Alfonso F; Cuesta J; Rivero F
    Rev Esp Cardiol (Engl Ed); 2021 Jul; 74(7):569-572. PubMed ID: 33622635
    [No Abstract]   [Full Text] [Related]  

  • 6. Bioresorbable Scaffolds for Coronary Artery Disease.
    Nathan A; Kobayashi T; Kolansky DM; Wilensky RL; Giri J
    Curr Cardiol Rep; 2017 Jan; 19(1):5. PubMed ID: 28108898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of everolimus-eluting bioresorbable scaffolds or everolimus-eluting stents in patients with acute myocardial infarction: two-year results of the randomised ISAR-Absorb MI trial.
    Wiebe J; Byrne RA; Alfonso F; Maeng M; Bradaric C; Kretov E; Cuesta J; Kuna C; Ibrahim T; Rivero F; Heugl M; Christiansen EH; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Cassese S
    EuroIntervention; 2022 Mar; 17(16):1348-1351. PubMed ID: 34702694
    [No Abstract]   [Full Text] [Related]  

  • 8. Bioresorbable scaffolds: zebras are not striped horses.
    Tarantini G; Cardaioli F
    Catheter Cardiovasc Interv; 2022 Mar; 99(4):1084-1085. PubMed ID: 35441824
    [No Abstract]   [Full Text] [Related]  

  • 9. Should we stop using bioresorbable scaffolds in coronary revascularisation?
    Mangieri A; Colombo A
    EuroIntervention; 2019 May; 15(1):28-30. PubMed ID: 31105070
    [No Abstract]   [Full Text] [Related]  

  • 10. A review of bioresorbable scaffolds: hype or hope?
    Tan HC; Ananthakrishna R
    Singapore Med J; 2017 Sep; 58(9):512-515. PubMed ID: 27868135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent.
    Ishibashi Y; Muramatsu T; Nakatani S; Sotomi Y; Suwannasom P; Grundeken MJ; Cho YK; Garcia-Garcia HM; van Boven AJ; Piek JJ; Sabaté M; Helqvist S; Baumbach A; McClean D; de Sousa Almeida M; Wasungu L; Miquel-Hebert K; Dudek D; Chevalier B; Onuma Y; Serruys PW
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1053-1063. PubMed ID: 26205444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Everolimus-eluting bioresorbable vascular scaffolds versus second generation drug-eluting stents for percutaneous treatment of chronic total coronary occlusions: Technical and procedural outcomes from the GHOST-CTO registry.
    La Manna A; Chisari A; Giacchi G; Capodanno D; Longo G; Di Silvestro M; Capranzano P; Tamburino C
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):E155-E163. PubMed ID: 26756959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No more metallic cages: an attractive hybrid strategy with bioresorbable vascular scaffold and drug-eluting balloon for diffuse or tandem lesions in the same vessel.
    Naganuma T; Latib A; Ielasi A; Panoulas VF; Sato K; Miyazaki T; Colombo A
    Int J Cardiol; 2014 Apr; 172(3):618-9. PubMed ID: 24495653
    [No Abstract]   [Full Text] [Related]  

  • 14. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioresorbable scaffolds versus everolimus-eluting metallic stents: five-year clinical outcomes of the randomised ABSORB II trial.
    Onuma Y; Chevalier B; Ono M; Cequier À; Dudek D; Haude M; Carrié D; Sabaté M; Windecker S; Rapoza RR; West NEJ; Reith S; de Sousa Almeida M; Campo G; Íñiguez-Romo A; Serruys PW
    EuroIntervention; 2020 Dec; 16(11):e938-e941. PubMed ID: 32515738
    [No Abstract]   [Full Text] [Related]  

  • 16. Outcome After Long-segment Stenting With Everolimus-eluting Bioresorbable Scaffolds Focusing on the Concept of Overlapping Implantation.
    Wiebe J; Dörr O; Liebetrau C; Bauer T; Wilkens E; Ilstad H; Boeder N; Elsässer A; Möllmann H; Hamm CW; Nef HM
    Rev Esp Cardiol (Engl Ed); 2016 Dec; 69(12):1144-1151. PubMed ID: 28134094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.
    Kandzari DE; Mauri L; Koolen JJ; Massaro JM; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    Lancet; 2017 Oct; 390(10105):1843-1852. PubMed ID: 28851504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bioresorbable Vascular Scaffold: A Focused Review on Development and Preclinical Studies].
    Ke L; Huang Y; Liu L; Duan X; Feng X; Wang C
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Feb; 42(2):115-118. PubMed ID: 29845812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioresorbable vascular scaffolds in left main coronary artery disease.
    Everaert B; Capranzano P; Tamburino C; Seth A; van Geuns RJ
    EuroIntervention; 2015; 11 Suppl V():V135-8. PubMed ID: 25983148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.